Actively Recruiting
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Led by Ou Bai, MD/PHD · Updated on 2026-03-25
50
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
CONDITIONS
Official Title
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 70 years or older
- No prior treatment for diffuse large B-cell lymphoma (DLBCL)
- Confirmed diagnosis of DLBCL, NOS, with CD20-positive cells
- MYC expression ≥ 40% and BCL2 expression ≥ 50% by immunohistochemistry
- Not diagnosed with double-hit or triple-hit lymphoma
- At least one FDG-avid lesion on PET-CT scan
- International Prognostic Index (IPI) score greater than 1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Laboratory tests meet specified blood counts and liver/kidney function limits without recent supportive treatment
- Life expectancy of at least 6 months
- Able to understand and voluntarily sign informed consent
You will not qualify if you...
- Central nervous system involvement
- Transformed lymphoma from other lymphoma types or specific DLBCL subtypes like primary CNS DLBCL
- Uncontrolled cardiovascular or cerebrovascular diseases, coagulation disorders, autoimmune diseases, or severe infections
- History of severe allergic or anaphylactic reactions to monoclonal antibodies or sensitivity to murine products
- Contraindications to any CHOP regimen component or chidamide
- HIV or hepatitis C infection
- Positive hepatitis B surface antigen with detectable HBV DNA or inability to confirm negative DNA in certain hepatitis B antibody cases
- Inability to follow study protocol due to psychiatric or unknown reasons
- Unwillingness or inability to use effective contraception during treatment and specified post-treatment periods
- Pregnant or breastfeeding women
- Other conditions considered unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Bethune Hospital of Jilin University
Changchun, Jilin, China, 130021
Actively Recruiting
Research Team
O
Ou Bai, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here